Eisai/Sysmex Link Hands On New Alzheimer’s Diagnostics
This article was originally published in PharmAsia News
Executive Summary
The ongoing roll-out of targeted oncology drugs requiring companion diagnostics continues to strengthen the links between therapeutics and diagnostics firms, and a new alliance between Japan's Eisai and Sysmex will further blur the divisions, this time in Alzheimer’s.